Jazz Pharmaceuticals grants 1,605 RSUs to director
LOVE TED W reported acquisition or exercise transactions in this Form 4 filing.
Rhea-AI Filing Summary
LOVE TED W reported acquisition or exercise transactions in this Form 4 filing.
Jazz Pharmaceuticals plc reported that director Ted W. Love received a grant of 1,605 restricted stock units, each representing a contingent right to receive one ordinary share at a cash price of $0.00 per share.
The award was granted under the company’s 2007 Amended and Restated Non-Employee Directors Stock Award Plan and will vest in full on July 23, 2027, subject to his continuous service and other conditions. Following this grant, Love directly holds 3,132 ordinary shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Ordinary Shares F1 | 1,605 | $0.00 | $0.00 |
Footnotes (1)
- F1. These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 23, 2027.
Key Figures
Key Terms
restricted stock units financial
contingent right financial
continuous service financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity award did JAZZ director Ted W. Love receive on August 5, 2026?
When do the 1,605 restricted stock units granted to JAZZ’s director vest?
Under what plan were Ted W. Love’s JAZZ restricted stock units granted?
Was Ted W. Love’s August 2026 JAZZ equity grant made under a Rule 10b5-1 plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.